Targeted Agents in Ovarian Carcinoma
Gynecologic malignancies take an important part in female cancers. Ovarian cancer is the second most common gynecologic cancer with the highest mortality rate in developed countries. Most of the patients need an adjuvant chemotherapy regimen after the initial surgery. Despite their suppressive effec...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Turaz Bilim
2016-06-01
|
| Series: | Medicine Science |
| Subjects: | |
| Online Access: | http://www.ejmanager.com/fulltextpdf.php?mno=195796 |
| _version_ | 1827360533426208768 |
|---|---|
| author | Murat Oz Ilker Selcuk Zafer Arik Tayfun Gungor |
| author_facet | Murat Oz Ilker Selcuk Zafer Arik Tayfun Gungor |
| author_sort | Murat Oz |
| collection | DOAJ |
| description | Gynecologic malignancies take an important part in female cancers. Ovarian cancer is the second most common gynecologic cancer with the highest mortality rate in developed countries. Most of the patients need an adjuvant chemotherapy regimen after the initial surgery. Despite their suppressive effect on tumor cells, much toxicity on healthy cells could be seen with these standard chemotherapeutics. In that manner a new way of tumor cell disruption with less toxicity and cancer selective effect is needed, which is called targeted therapy. Moreover this approach could prevent chemo-resistance and increase chemo-sensitivity of the disease. Primary cytoreductive surgery with platinum based chemotherapy shape the initial management of these tumors. However, recently we are on the edge of molecular therapy for this cancer. In this setting we need to identify a dominant biological pathway for tumor progression and discover a functional and structural molecule within this pathway. The new therapeutic modalities with targeted molecules should build up new perspectives insight tumor cell behaviour. Agents against angiogenesis and receptors of growth factors in addition to signalling cascades and intracellular enzymes could shape the individual treatment protocols for cancer survivors. [Med-Science 2016; 5(2.000): 547-61] |
| first_indexed | 2024-03-08T06:48:36Z |
| format | Article |
| id | doaj.art-e29d16018b6e4e8082d6ee211fbc6507 |
| institution | Directory Open Access Journal |
| issn | 2147-0634 |
| language | English |
| last_indexed | 2024-03-08T06:48:36Z |
| publishDate | 2016-06-01 |
| publisher | Society of Turaz Bilim |
| record_format | Article |
| series | Medicine Science |
| spelling | doaj.art-e29d16018b6e4e8082d6ee211fbc65072024-02-03T07:28:54ZengSociety of Turaz BilimMedicine Science2147-06342016-06-01525476110.5455/medscience.2015.04.8351195796Targeted Agents in Ovarian CarcinomaMurat Oz0Ilker Selcuk1Zafer Arik2Tayfun Gungor3Zekai Tahir Burak Women's Health Education and Training Hospital Department of Gynecologic Oncology Zekai Tahir Burak Women's Health Education and Training Hospital Department of Gynecologic Oncology Zekai Tahir Burak Women's Health Education and Training Hospital Department of Medical Oncology Hitit Universitiy Faculty of Obstetrics and GynecologyGynecologic malignancies take an important part in female cancers. Ovarian cancer is the second most common gynecologic cancer with the highest mortality rate in developed countries. Most of the patients need an adjuvant chemotherapy regimen after the initial surgery. Despite their suppressive effect on tumor cells, much toxicity on healthy cells could be seen with these standard chemotherapeutics. In that manner a new way of tumor cell disruption with less toxicity and cancer selective effect is needed, which is called targeted therapy. Moreover this approach could prevent chemo-resistance and increase chemo-sensitivity of the disease. Primary cytoreductive surgery with platinum based chemotherapy shape the initial management of these tumors. However, recently we are on the edge of molecular therapy for this cancer. In this setting we need to identify a dominant biological pathway for tumor progression and discover a functional and structural molecule within this pathway. The new therapeutic modalities with targeted molecules should build up new perspectives insight tumor cell behaviour. Agents against angiogenesis and receptors of growth factors in addition to signalling cascades and intracellular enzymes could shape the individual treatment protocols for cancer survivors. [Med-Science 2016; 5(2.000): 547-61]http://www.ejmanager.com/fulltextpdf.php?mno=195796targeted therapyovarian carcinomachemotherapy |
| spellingShingle | Murat Oz Ilker Selcuk Zafer Arik Tayfun Gungor Targeted Agents in Ovarian Carcinoma Medicine Science targeted therapy ovarian carcinoma chemotherapy |
| title | Targeted Agents in Ovarian Carcinoma |
| title_full | Targeted Agents in Ovarian Carcinoma |
| title_fullStr | Targeted Agents in Ovarian Carcinoma |
| title_full_unstemmed | Targeted Agents in Ovarian Carcinoma |
| title_short | Targeted Agents in Ovarian Carcinoma |
| title_sort | targeted agents in ovarian carcinoma |
| topic | targeted therapy ovarian carcinoma chemotherapy |
| url | http://www.ejmanager.com/fulltextpdf.php?mno=195796 |
| work_keys_str_mv | AT muratoz targetedagentsinovariancarcinoma AT ilkerselcuk targetedagentsinovariancarcinoma AT zaferarik targetedagentsinovariancarcinoma AT tayfungungor targetedagentsinovariancarcinoma |